Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Daiichi Sankyo Europe GmbH announced that results from the 12-week, pivotal Phase 3 bempedoic acid / ezetimibe FDC tablet study (also known as Study 053) were published in the European Journal of Preventative Cardiology.
A new high-resolution approach using portable DNA sequencers provides a more complete genomic picture of antibiotic resistance in gut bacteria
As reported yesterday, the Trump administration is evaluating proposals to allow consumers to buy drugs legally from Canada. Today, their efforts became more official as the U.S. Department of Health and Human Services announced their intentions.
Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.
Company Offers Novel Ebola Vaccine for Public Health use...Gratis
TLC announced financial results for the second quarter ended June 30, 2019, and provided a business update.
Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.
On July 18, it was reported by Reuters that Canada is opposed to any U.S. plans to buy Canadian prescription drugs because the country fears it will threaten its own drug supply or raise costs for its own people.
Teva Pharmaceuticals, Endo Pharmaceuticals and Taikoku Pharma entered into settlement agreements with the State of California for a total of almost $70 million. The settlements were over non-competitive, inter-company deals that prevented cheaper drugs from entering the market.
Specifically, the civil subpoenas were issued to determine if the company had violated antitrust laws with its rheumatoid arthritis drug Remicade.